1. No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib monotherapy groups. 2. Serious adverse events ...
Patients in sparsentan group reported a 50% reduction in proteinuria compared to 15% in the irbesartan group at week ...
1. Patients in sparsentan group reported a 50% reduction in proteinuria compared to 15% in the irbesartan group at week ...
1. Risk of major adverse cardiac events increased amongst patients with a specific glomerular disease, including non-proliferative glomerulopathy, renal vascular ...
1. The mean eGFR slope was comparable among patients allocated to sodium bicarbonate and placebo over 24 months. 2. Sodium ...
1. In this scoping review, religiosity and spirituality (R/S) were positively associated with the well-being of kidney transplant recipients, primarily ...
1. In a group of patients undergoing endoscopic removal of symptomatic kidney stones, concurrent removal of asymptomatic stones significantly reduced ...
1. Older age, male sex, and pre-existing comorbidities were independent risk factors for developing complications following COVID-19 infection. 2. The ...
1. Lenvatinib plus pembrolizumab was superior to sunitinib in overall survival for patients with advanced renal cell carcinoma. 2. Lenvatinib ...
1. The median number of RRT-free days was 12 days (IQR 0-25) in the delayed strategy and 10 days (IQR ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
